Nasal Polyps Treatment Market Size
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
CAGR | > 6.20 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Nasal Polyps Treatment Market Analysis
The Nasal Polyps Treatment Market is anticipated to witness a CAGR of nearly 6.2% during the forecast period. The major factors driving the growth of the market are the rising prevalence of various cancers, immunological disorders, and the increasing geriatric population.
For instance, the Centers for Disease Control and Prevention reports that in 2018, about 28.9 million adults in the United States were diagnosed with sinusitis which directly resulted in higher demand for the treatment fueling the growth of the market.
Furthermore, an increase in the R&D investment in pharmaceuticals with a strong pipeline of products is expected to boost the growth of the global market throughout the forecasted period.
Nasal Polyps Treatment Market Trends
This section covers the major market trends shaping the Nasal Polyps Treatment Market according to our research experts:
Corticosteroids Segment by Drug Class is Expected to Hold the Largest Market Share in the Nasal Polyps Treatment Market
The corticosteroid segment is expected to account for the largest market share due to the increase in the demand for corticosteroids treatment and its availability in various dosage forms like injections, intranasal sprays, and drops according to the need of the patient. Also, the availability of various corticosteroids as topical formulations and aerosols which have the ability to decrease the size of nasal polyps, and thus heal the nasal polyps in patients has contributed to the significant share of revenue in the market. Furthermore, patient compliance for creams is more compared to other dosage forms available in the market.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall nasal polyps treatment market throughout the forecast period. This is mainly due to the increasing incidence of various cancers and allergic disorders such as asthma, sinusitis, and more, research activities in the United States coupled with increased approvals from regulatory bodies are likely to drive the growth of the nasal polyps treatment market.
The Asia Pacific is set to grow at the fastest rate during the forecast period, driven by the prevalence of allergic disorders and the steady growth of the pharmaceutical industry in recent years. China plays a pivotal role due in the Asia region to its high population and high extent of government initiatives to the healthcare sector. Ongoing trials in the region will further stimulate market growth in the region.
Nasal Polyps Treatment Industry Overview
The Nasal Polyps Treatment Market is moderately competitive and consists of several major players. Few of the major players are developing novel delivery systems to treat nasal polyps. which is expected to impel the global nasal polypstreatment market growth. For instance, in 2018, Intersect ENT Inc. launched SINUVA, a sinus implant containing mometasone furoate that is used to treat nasal polyps. Futhermore, few key players are entering into partnerships to develop and increase their market position globally. Some of the companies which are currently dominating the market are Sanofi S.A, OptiNose US, Merck & Co Inc, Intersect ENT Inc, and GlaxoSmithKline PLC
Nasal Polyps Treatment Market Leaders
-
Sanofi S.A
-
OptiNose US
-
Merck & Co Inc
-
Intersect ENT Inc
-
GlaxoSmithKline PLC
*Disclaimer: Major Players sorted in no particular order
Nasal Polyps Treatment Market Report - Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Rising Prevalence of Various Immunological Disorders along with the Increasing Geriatric Population
-
4.2.2 Huge Product Pipeline of Nasal Polyps Treatment with Growing Research Activities
-
-
4.3 Market Restraints
-
4.3.1 High Cost and Complications Associated with Sinus Surgeries
-
4.3.2 Adverse Reactions Associated with Steroid Therapies
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Drug Class
-
5.1.1 Corticosteroids
-
5.1.2 Antibiotics
-
5.1.3 Leukotriene Inhibitors
-
5.1.4 Others
-
-
5.2 By Route of Administration
-
5.2.1 Oral
-
5.2.2 Nasal
-
5.2.3 Others
-
-
5.3 By Distribution Channel
-
5.3.1 Hospital Pharmacies
-
5.3.2 Retail Pharmacies
-
5.3.3 Online Pharmacies
-
-
5.4 Geography
-
5.4.1 North America
-
5.4.1.1 United states
-
5.4.1.2 Canada
-
5.4.1.3 Mexico
-
-
5.4.2 Europe
-
5.4.2.1 Germany
-
5.4.2.2 United Kingdom
-
5.4.2.3 France
-
5.4.2.4 Italy
-
5.4.2.5 Spain
-
5.4.2.6 Rest of Europe
-
-
5.4.3 Asia-Pacific
-
5.4.3.1 China
-
5.4.3.2 Japan
-
5.4.3.3 India
-
5.4.3.4 Australia
-
5.4.3.5 South Korea
-
5.4.3.6 Rest of Asia-Pacific
-
-
5.4.4 Middle-East and Africa
-
5.4.4.1 GCC
-
5.4.4.2 South Africa
-
5.4.4.3 Rest of Middle-East and Africa
-
-
5.4.5 South America
-
5.4.5.1 Brazil
-
5.4.5.2 Argentina
-
5.4.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Sanofi S.A
-
6.1.2 OptiNose US
-
6.1.3 Merck & Co Inc.
-
6.1.4 Intersect ENT Inc.
-
6.1.5 GlaxoSmithKline PLC
-
6.1.6 Teva Pharmaceutical Industries Ltd.
-
6.1.7 Regeneron Pharmaceuticals Inc.
-
6.1.8 F. Hoffmann-La Roche AG
-
6.1.9 Novartis International AG
-
6.1.10 Norton Waterford Ltd
-
6.1.11 Pfizer Inc.
-
- *List Not Exhaustive
-
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Nasal Polyps Treatment Industry Segmentation
As per the scope of the report, nasal polyps are soft, painless, fleshy benign growths inside the paranasal sinuses and in the lining of the nose due to chronic inflammation of the mucosa. Generally, nasal polyps may occur due to asthma, allergic infections, sinus infections, cystic fibrosis, etc. The major symptoms associated with nasal polyps are nasal congestion, sinofacial pain, and loss of sense of smell.
By Drug Class | |
Corticosteroids | |
Antibiotics | |
Leukotriene Inhibitors | |
Others |
By Route of Administration | |
Oral | |
Nasal | |
Others |
By Distribution Channel | |
Hospital Pharmacies | |
Retail Pharmacies | |
Online Pharmacies |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Nasal Polyps Treatment Market Research FAQs
What is the current Nasal Polyps Treatment Market size?
The Nasal Polyps Treatment Market is projected to register a CAGR of greater than 6.20% during the forecast period (2024-2029)
Who are the key players in Nasal Polyps Treatment Market?
Sanofi S.A, OptiNose US, Merck & Co Inc, Intersect ENT Inc and GlaxoSmithKline PLC are the major companies operating in the Nasal Polyps Treatment Market.
Which is the fastest growing region in Nasal Polyps Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Nasal Polyps Treatment Market?
In 2024, the North America accounts for the largest market share in Nasal Polyps Treatment Market.
What years does this Nasal Polyps Treatment Market cover?
The report covers the Nasal Polyps Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Nasal Polyps Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Polyps Industry Report
Statistics for the 2024 Polyps market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Polyps analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.